MN HF4064

Commissioner of Health must conduct a comprehensive study on Minnesota's capacity for rare disease cell and gene therapy research, development, delivery, and access, in consultation with the University of Minnesota and the Minnesota Rare Disease Advisory Council

Study must assess 10 areas including: other states' capabilities, clinical trial capacity, biomanufacturing opportunities, health system delivery readiness, workforce needs, payment policies under Medicaid and commercial insurers, regulatory barriers, and health equity issues for rural and underserved communities

Commissioner must seek input from patients, caregivers, advocacy groups, health care providers, academic institutions, payers, pharmacy benefit managers, and biotechnology/pharmaceutical industries

Report due to the legislature by January 1, 2028, with findings, short-term and long-term recommendations for state investments and policy changes, and identification of federal funding opportunities and public-private partnerships

One-time general fund appropriation in fiscal year 2027 (amount unspecified in bill text) available through June 30, 2028